『Biopharma's $1.1B Late-Stage Surge Inside a Down Quarter』のカバーアート

Biopharma's $1.1B Late-Stage Surge Inside a Down Quarter

Biopharma's $1.1B Late-Stage Surge Inside a Down Quarter

無料で聴く

ポッドキャストの詳細を見る
Q1 2026 biopharma venture data looks ugly on the surface — fewer deals, less total capital. But buried inside the same dataset is a story of radical selectivity: late-stage funding nearly quadrupled while the Series C middle got gutted. Alex Rock breaks down what the numbers actually signal and what it means for where capital is flowing next.
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません